The last 5 years have seen a major upturn in the fortune of therapeutic monoclonal antibodies (mAbs), with nine mAbs approved for clinical use during this period and more than 70 now in clinical trials beyond phase II. Sales are expected to reach $4 billion per annum worldwide in 2002 and $15 billion by 2010. This success can be related to the engineering of mouse mAbs into mouse/human chimaeric antibodies or humanized antibodies, which have had a major effect on immunogenicity, effector function and half-life. The issue of repeated antibody dosing at high levels with limited toxicity was essential for successful clinical applications. Emerging technologies (phage display, human antibody-engineered mice) have created a vast range of novel, antibody-based therapeutics, which specifically target clinical biomarkers of disease. Modified recombinant antibodies have been designed to be more cytotoxic (toxin delivery), to enhance effector functions (bivalent mAbs) and to be fused with enzymes for prodrug therapy and cancer treatment. Antibody fragments have also been engineered to retain specificity and have increased the penetrability of solid tumours (single-chain variable fragments). Radiolabelling of antibodies has now been shown to be effective for cancer imaging and targeting. This article focuses on developments in the design and clinical use of recombinant antibodies for cancer therapy.
Skip Nav Destination
Article navigation
April 2003
- PDF Icon PDF LinkFront Matter
Conference Article|
April 01 2003
The role of therapeutic antibodies in drug discovery
L.H. Stockwin;
L.H. Stockwin
Therapeutic Antibody Division, Oxford Glycosciences [UK] Ltd., The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K.
Search for other works by this author on:
S. Holmes
S. Holmes
1
Therapeutic Antibody Division, Oxford Glycosciences [UK] Ltd., The Forum, 86 Milton Park, Abingdon, Oxfordshire OX14 4RY, U.K.
1To whom correspondence should be addressed (e-mail Steve.Holmes@ogs.co.uk).
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8752
Print ISSN: 0300-5127
Copyright 2003 Biochemical Society
2003
Biochem Soc Trans (2003) 31 (2): 433–436.
Citation
L.H. Stockwin, S. Holmes; The role of therapeutic antibodies in drug discovery. Biochem Soc Trans 1 April 2003; 31 (2): 433–436. doi: https://doi.org/10.1042/bst0310433
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.